Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol

Pharmazie

Volumn 66, Issue 3, 2011, Pages 216-221

  Qu, Yan Qing ^a   Fang, Zhong Ze ^b,c   Yang, Ling ^b   Gao, Zhen Ming ^a   Liang, Rui ^a   Zhu, Liang Liang ^b,c   Dong, Pei Pei ^b,c   Zhang, Yan Yan ^b,c   Ge, Guang Bo ^b   Wang, Li Ming ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIETHYLSTILBESTROL; DOCETAXEL; FOSFESTROL; CARCINOGEN; DRUG; ENZYME INHIBITOR; ISOENZYME;

ARTICLE; DRUG INHIBITION; DRUG INTERACTION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; AREA UNDER THE CURVE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; KINETICS; LIVER; LIVER MICROSOME; METABOLISM;

AREA UNDER CURVE; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; DIETHYLSTILBESTROL; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; LIVER; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

EID: 79957508702     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0241     Document Type: Article

References (20)

1. Bachmann KA, Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39: 1064-1072. (Pubitemid 40695974)
2. Fang ZZ, Zhang YY, Ge GB, Hno H, Liang SC, Yang L (2010) Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 69: 193-199.
3. Gardner WU, Dougherty TF, Williams WL (1944) Lymphoid tumors in mice receiving steroid hormones. Cancer Res 4: 73-87.
4. Guengerich FP (2006) Cytochrome P450 s and other enzymes in drug metabolism and toxicity. AAPS J 8: E101-E111.
5. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50: 387-412.
6. Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73: 67-74. (Pubitemid 26425815)
7. Lowry OH, Rosebrough NJ, Farr AL, Randall, RJ (1951) Protein measurement with the Folin phenol agent. J Biol Chem 193: 265-275.
8. McMartin KE, Kennedy KA, Greenspan P, Alam SN, Greiner P, Yam J (1978) Diethylstilboestrol: A review of its toxicity and use as a growth promotant in food-producing animals. J Environ Pathol Toxicol Oncol 1: 279-313. (Pubitemid 10220624)
9. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM (2007) Diethylstilbestrol and docetaxel-A phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 110: 996-1002. (Pubitemid 47312864)
10. Nakamura K (1986) Bioavailability, distribution and pharmacokinetics of diethylstilbestrol converted from diethylstilbestrol diphosphate in patients with prostate cancer. Hirosihma J Med Sci 35: 325-338.
11. Nomura T, Kanzaki T (1977) Introduction of urogenital anomalies and some tumors in the progeny of mice receiving diethylstilboestrol during pregnancy. Cancer Res 37: 1099-1104. (Pubitemid 8088181)
12. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. J Biol Chem 239: 2370-2385.
13. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL (1999) Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. Breast Cancer Res Treat 54: 117-122. (Pubitemid 29295314)
14. Purnapatre K, Khattar SK, Saini KS (2008) Cytochrome P450 s in the development of target-based anticancer drugs. Cancer Lett 259: 1-15. (Pubitemid 350253101)
15. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ (1998) A phase II trial of oral diethylstilboestrol as a second-line hormonal agent in advanced prostate cancer. Urology 52: 257-260. (Pubitemid 28357829)
16. Soars MG, McGinnity DF, Grime K, Riley RJ (2007) The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168: 2-15. (Pubitemid 46661937)
17. Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. Br J Clin Pharmacol 52: 107-117. (Pubitemid 32862777)
18. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56: 601-607. (Pubitemid 124006567)
19. Zhang JW, Liu Y, Li W, Hao DC, Yang L (2006) Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes. Eur J Clin Pharmacol 62: 497-502.
20. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, Yang L (2009) Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39: 283-292.